A multicenter phase II randomized controlled trial comparing 177Lu-Dotatate/capecitabine combination treatment with 177Lu-Dotatate monotherapy in patients with neuroendocrine tumors

Key Points

• 177Lu-Dotatate/capecitabine did not improve overall response rate in advanced neuroendocrine tumors, and
• Patients receiving combination therapy displayed reduced quality-adjusted life years compared to monotherapy.
• The study was a phase II randomized controlled trial assessing treatment effectiveness among advanced neuroendocrine tumors.
• Findings suggest that combining capecitabine with 177Lu-Dotatate may not confer additional survival benefits, emphasizing monotherapy.

Abstract